(S)-2-Fmoc-amino-3-{2-[bis(tert-butoxycarbonylmethyl)amino]acetylamino}propionic acid | 1283592-37-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 芴
• 英文名称: (S)-2-Fmoc-amino-3-{2-[bis(tert-butoxycarbonylmethyl)amino]acetylamino}propionic acid
• 英文别名: (2S)-3-[[2-[bis[2-[(2-methylpropan-2-yl)oxy]-2-oxoethyl]amino]acetyl]amino]-2-(9H-fluoren-9-ylmethoxycarbonylamino)propanoic acid
• CAS: 1283592-37-9
• 化学式: C₃₂H₄₁N₃O₉
• 分子量: 611.692
• InChiKey: MBWMDIVXTWWMJR-VWLOTQADSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  44
• 可旋转键数：
  17
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  161
• 氢给体数：
  3
• 氢受体数：
  10

反应信息

• 作为产物：
  描述：

  (S)-3-amino-2-(9H-fluoren-9-ylmethoxycarbonylamino)propionic acid 、 bis(tert-butoxycarbonylmethyl)aminoacetic acid 2,5-dioxo-pyrrolidin-1-yl ester 以 四氢呋喃 为溶剂， 以64%的产率得到(S)-2-Fmoc-amino-3-{2-[bis(tert-butoxycarbonylmethyl)amino]acetylamino}propionic acid
  参考文献：
  名称：

  Peptides for Treatment of Obesity

  摘要：

  本发明涉及一种新型肽化合物，其有效调节一个或多个黑色素皮质素受体类型，以及该类化合物在治疗中的应用，包括通过将该类化合物用于需要的患者进行治疗的方法，以及该类化合物在制造药物中的应用。本发明的化合物在治疗肥胖以及与肥胖相关的各种疾病或症状方面具有特别的兴趣。

  公开号：

  US20130012432A1

文献信息

• PEPTIDES FOR TREATMENT OF OBESITY
  申请人：Novo Nordisk A/S

  公开号：EP2370104A1

  公开（公告）日：2011-10-05
• [EN] PEPTIDES FOR TREATMENT OF OBESITY<br/>[FR] PEPTIDES POUR LE TRAITEMENT DE L'OBÉSITÉ
  申请人：NOVO NORDISK AS

  公开号：WO2010060901A1

  公开（公告）日：2010-06-03

  The present invention relates to novel peptide compounds which are effective in modulating one or more melanocortin receptor types, to the use of the compounds in therapy, to methods of treatment comprising administration of the compounds to patients in need thereof, and to the use of the compounds in the manufacture of medicaments. The compounds of the invention are of particular interest in relation to the treatment of obesity as well as a variety of diseases or conditions associated with obesity.
• [EN] PEPTIDES FOR TREATMENT OF OBESITY<br/>[FR] PEPTIDES DE TRAITEMENT DE L'OBÉSITÉ
  申请人：NOVO NORDISK AS

  公开号：WO2011104378A1

  公开（公告）日：2011-09-01

  The present invention relates to novel peptide compounds which are effective in modulating one or more melanocortin receptor types, to the use of the compounds in therapy, to methods of treatment comprising administration of the compounds to patients in need thereof, and to the use of the compounds in the manufacture of medicaments. The compounds of the invention are of particular interest in relation to the treatment of obesity as well as a variety of diseases or conditions associated with obesity.